A Phase 4 interventional study of Everolimus and Tacrolimus in Liver Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 15 sites in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-05-10.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial evaluated the efficacy and safety of Everolimus in combination with tacrolimus versus a standard immunosuppressive regimen concerning kidney function in liver transplant recipients.
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female recipients of a full-size liver allograft, aged 18 to 65 years.
Exclusion criteria:
Patients with thrombocytopenia ( \<50,000/mm³), with an of \<1,000/mm³ or leucopenia (leucocytes \<2000/mm³), with anemia with \< 6g/dl at time of randomization
Patients with uncontrolled hypercholesterolemia (>350mg/dL; >9mmol/L) or hypertriglyceridemia (>750 mg/dL; >8.5 mmol/L) at time of randomization
History of of any organ system within the past 5 years whether or not there is evidence of local recurrence or , other than non-metastatic basal or squamous cell carcinoma of the skin or HCC
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: \< 5 ng/mL)
Drug: Everolimus · Drug: Tacrolimus · Drug: Corticosteroids
Tacrolimus (C0-h: 6-10 ng/ml)
Drug: Tacrolimus · Drug: Corticosteroids
tablet containing 0.25mg, 0.5mg, 0.75mg or 1.0mg
Also known as: RAD001 / Certican
capsule containing 0.5, 1.0, or 5.0mg
Also known as: Tacrolimus Hexal
For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids may have been used for the duration of the study according to the investigator's discretion, but may not have been eliminated sooner than 6 months post-transplantation.
Estimated Glomerular Filtration Rate (GFR)
The estmated GFR was calculated using MDRD-4 formula (Modification of Diet in Renal Disease Study Group).
Time frame: month 12
Estimated GFR - PP Set
This was a sensitivity analysis for the primary outcome measure based on the per-protocol set of patients.
Time frame: month 12
Percentage of Participants With Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death
Percentage of Participants with Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death at Month 12
Time frame: 12 months
Number of Participants With HCV
Number of Participants with HCV (hepatitis C virus) assessed as treatment emergent adverse events of special interest
Time frame: 12 months
Incidence of HCV Related Fibrosis
Incidence of hepatitis C virus (HCV) related fibrosis assessed as treatment emergent adverse events of special interest
Time frame: 12 months
Incidence of de Novo HCC Malignancies
Incidence of de novo Hepatocellular Carcinoma (HCC) malignancies assessed as treatment emergent adverse events of special interest
Time frame: 12 months
Incidence and Severity of CMV Viral Infections.
Incidence and severity of cytomegalovirus (CMV) viral infections assessed as treatment emergent adverse events of special interest.
Time frame: 12 months
In total, 642 patients were screened for study eligibility at 15 study centers in Germany. 339 patients were randomized out of which 333 received study treatment and were included in the analyses.
| Milestone | Everolimus/Tacrolimus | Tacrolimus |
|---|---|---|
| Started | 171 | 168 |
| Full anylsis set (fas) | 169 | 164 |
| Safety set | 169 | 164 |
| Per protocol set (pp) | 110 | 101 |
| Completed | 166 | 148 |
| Not completed | 5 | 20 |
| Withdrew: Graft loss/retransplantation | 0 | 1 |
| Withdrew: Administrative problems | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 7 |
| Withdrew: Death | 2 | 4 |
| Withdrew: Never received study treatment | 2 | 4 |
The estmated GFR was calculated using MDRD-4 formula (Modification of Diet in Renal Disease Study Group).
| mL/min | Everolimus/Tacrolimus | Tacrolimus |
|---|---|---|
| Estimated Glomerular Filtration Rate (GFR) | 73.46 ± 25.57 | 71.95 ± 27.17 |
This was a sensitivity analysis for the primary outcome measure based on the per-protocol set of patients.
| mL/min | Everolimus/Tacrolimus | Tacrolimus |
|---|---|---|
| Estimated GFR - PP Set | 74.83 ± 25.19 | 70.65 ± 24.91 |
Percentage of Participants with Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death at Month 12
| Percent of Patients | Everolimus/Tacrolimus | Tacrolimus |
|---|---|---|
| Percentage of Participants With Treated Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death | 9.5 | 7.9 |
Number of Participants with HCV (hepatitis C virus) assessed as treatment emergent adverse events of special interest
| Participants | Everolimus/Tacrolimus | Tacrolimus |
|---|---|---|
| Number of Participants With HCV | 6 | 12 |
Incidence of hepatitis C virus (HCV) related fibrosis assessed as treatment emergent adverse events of special interest
| Participants | Everolimus/Tacrolimus | Tacrolimus |
|---|---|---|
| Incidence of HCV Related Fibrosis | 1 | 0 |
Incidence of de novo Hepatocellular Carcinoma (HCC) malignancies assessed as treatment emergent adverse events of special interest
| Participants | Everolimus/Tacrolimus | Tacrolimus |
|---|---|---|
| Incidence of de Novo HCC Malignancies | 0 | 2 |
Incidence and severity of cytomegalovirus (CMV) viral infections assessed as treatment emergent adverse events of special interest.
| Participants | Everolimus/Tacrolimus | Tacrolimus |
|---|---|---|
| No CMV viral infection | 136 | 129 |
| Asymptomatic | 0 | 5 |
| Mild | 16 | 20 |
| Moderate | 13 | 9 |
| Severe | 4 | 1 |
Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit up to approximately 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus/Tacrolimus | 3/169 (1.8%) | 111/169 (65.7%) | 164/169 (97%) |
| Tacrolimus | 4/164 (2.4%) | 101/164 (61.6%) | 153/164 (93.3%) |
| Event | Everolimus/Tacrolimus | Tacrolimus |
|---|---|---|
| BILIARY ANASTOMOSIS COMPLICATIONInjury, poisoning and procedural complications | 8/169 | 13/164 |
| CHOLANGITISHepatobiliary disorders | 13/169 | 7/164 |
| LIVER TRANSPLANT REJECTIONImmune system disorders | 12/169 | 9/164 |
| INCISIONAL HERNIAInjury, poisoning and procedural complications | 11/169 | 4/164 |
| PNEUMONIAInfections and infestations | 10/169 | 7/164 |
| ACUTE KIDNEY INJURYRenal and urinary disorders | 10/169 | 8/164 |
| HEPATIC ENZYME INCREASEDInvestigations | 6/169 | 7/164 |
| BILE DUCT STENOSISHepatobiliary disorders | 5/169 | 6/164 |
| TRANSAMINASES INCREASEDInvestigations | 2/169 | 6/164 |
| CHOLANGITIS INFECTIVEInfections and infestations | 6/169 | 1/164 |
| Event | Everolimus/Tacrolimus | Tacrolimus |
|---|---|---|
| HEADACHENervous system disorders | 48/169 | 22/164 |
| LEUKOPENIABlood and lymphatic system disorders | 45/169 | 12/164 |
| DIARRHOEAGastrointestinal disorders | 43/169 | 39/164 |
| VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 41/169 | 29/164 |
| OEDEMA PERIPHERALGeneral disorders | 38/169 | 15/164 |
| INCISIONAL HERNIAInjury, poisoning and procedural complications | 35/169 | 10/164 |
| URINARY TRACT INFECTIONInfections and infestations | 30/169 | 24/164 |
| HYPERCHOLESTEROLAEMIAMetabolism and nutrition disorders | 30/169 | 9/164 |
| CYTOMEGALOVIRUS INFECTIONInfections and infestations | 24/169 | 28/164 |
| HYPERTENSIONVascular disorders | 28/169 | 24/164 |
| Age, Continuous(Years) | Everolimus/Tacrolimus | Tacrolimus | Total |
|---|---|---|---|
| Mean | 53.68 ± 9.38 | 53.46 ± 9.64 | 53.57 ± 9.49 |
| Sex: Female, Male(Participants) | Everolimus/Tacrolimus | Tacrolimus | Total |
|---|---|---|---|
| Female | 36 | 43 | 79 |
| Male | 133 | 121 | 254 |
| Race/Ethnicity, Customized(Participants) | Everolimus/Tacrolimus | Tacrolimus | Total |
|---|---|---|---|
| Caucasian | 168 | 157 | 325 |
| Black | 1 | 1 | 2 |
| Asian | 0 | 3 | 3 |
| Other | 0 | 3 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2012 to primary completion in Aug 2017, 62 months.
Results were first posted in May 2019, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus